Previsioni

Il prezzo obiettivo medio degli analisti è 65,95 € (+8,51%). La mediana è 72,99 € (+20,09%).

Acquista	16
Mantieni	8
Vendi	1

Notizie Vai al feed delle notizie

Cooper Companies announces quarterly results for period ending 31 July 2026

Cooper Companies will likely publish results for the quarter ending 31 July 2026 on 9 September 2026. Fifteen analysts expect an average EPS of $1.12 per share versus $0.49 in the year-ago quarter. The revenue forecast averages $1.10 billion, an increase of 3.63% from $1.06 billion a year earlier. For the current fiscal year, analysts predict a median EPS of $4.63 and total revenue of $4.31 billion. » Altro su finanzen.net
Oakmark adds The Cooper Companies after pullback creates attractive entry point

Oakmark Global Fund initiated a position in The Cooper Companies, citing its strong contact-lens market position, recurring revenues, specialty-lens share gains and private-label strategy. The fund noted recent steps to improve free cash flow conversion, reaccelerate growth and optimize the product portfolio. Cooper's stock has pulled back with the med-tech sector and now trades at a meaningful discount to peers and its own history; it closed at $68.51 with a market cap of $13.36 billion. » Altro su finance.yahoo.com
Cooper Companies with record quarter and raised guidance drives institutional buying

Cooper Companies reported excellent quarterly results with sharply higher revenue and profit and strong margin improvement. The company raised its full-year 2026 guidance. Large investors then significantly increased their purchases, leading to a volume and price breakout of over 5%. Sustainable growth is expected mainly due to rising global demand for vision care products. » Altro su finanzen.net

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 1999, Cooper Companies ha già distribuito 0,00244 € di dividendi. L'ultimo pagamento è avvenuto a luglio 1999.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Cooper Companies ha registrato ricavi pari a 922,09 Mln € e un utile netto di -66,42 Mln €

(EUR)	apr 2026	YoY
Ricavi	922,09 Mln	4,18%
Utile lordo	627 Mln	4,55%
Utile netto	-66,42 Mln	185,76%
EBITDA	57,89 Mln	74,91%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	12,17 Mld €
Numero di azioni	195,03 Mln
Massimo/minimo a 52 settimane	77,14 € - 50,57 €
Dividendi	No
Beta	0,82
Rapporto P/E	61,59
Rapporto PEG	-1,42
Rapporto P/B	1,72
Rapporto P/S	3,35

Profilo aziendale

The Cooper Companies, Inc. entwickelt, produziert und vertreibt zusammen mit ihren Tochtergesellschaften Kontaktlinsen. Das Unternehmen ist in zwei Segmenten tätig, CooperVision und CooperSurgical. Das Segment CooperVision bietet sphärische Linsen, einschließlich Linsen, die Kurz- und Weitsichtigkeit korrigieren, sowie torische und multifokale Linsen, die Linsen zur Korrektur von Sehproblemen wie Astigmatismus, Alterssichtigkeit, Kurzsichtigkeit, Augentrockenheit und Augenermüdung in Amerika, Europa, dem Nahen Osten, Afrika und dem asiatisch-pazifischen Raum umfassen. Das Segment CooperSurgical konzentriert sich auf die Familien- und Frauengesundheitspflege, die medizinische Geräte, Fruchtbarkeit, Genomik, Diagnostik und Empfängnisverhütung für medizinisches Fachpersonal und Patienten weltweit anbietet. Es bietet chirurgische und Büroprodukte, einschließlich PARAGARD, Uterusmanipulatoren, Retraktoren, Verschlussprodukte, Point-of-Care-Produkte, LEEP-Produkte, Endosee sowie Illuminate- und Fötus-Kissen; Fruchtbarkeitsprodukte und -dienstleistungen, wie Fruchtbarkeitsverbrauchsmaterial und -ausrüstung sowie Embryo-Optionen und Präimplantations-Gentests. The Cooper Companies, Inc. wurde 1958 gegründet und hat seinen Hauptsitz in San Ramon, Kalifornien.

Nome	Cooper Companies
CEO	Albert G. White
Sede centrale	San Ramon, ca Stati Uniti
Sito web	coopercos.com
Settore	Sanità
Industria	Attrezzature e forniture sanitarie
Quotazione in borsa	21/01/1983
Dipendenti	15.000